Legend Biotech
LEGN
181 hedge funds and large institutions have $4.06B invested in Legend Biotech in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 80 increasing their positions, 49 reducing their positions, and 37 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 49
1.39% more ownership
Funds ownership: 23.78% → 25.17% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
6% less funds holding
Funds holding: 192 → 181 (-11)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
16% less capital invested
Capital invested by funds: $4.85B → $4.06B (-$797M)
23% less call options, than puts
Call options by funds: $18.3M | Put options by funds: $23.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$117M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$68M |
| 3 |
Millennium Management
New York
|
+$59.4M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$30.1M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$134M |
| 2 |
Holocene Advisors
New York
|
-$42.7M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$41.2M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$35.9M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$21.5M |
LEGN Hedge Fund Activity: Q2 2024 in Review
181 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2024, worth a combined $4.06B — down 16% from $4.85B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of LEGN and 31 opened new positions — a net loss of 6 holders — while 49 trimmed existing stakes and 80 added.
The largest buyer was Westfield Capital Management, adding an estimated $117M. The largest seller was Capital World Investors, exiting entirely with an estimated $134M sold.
- 181 institutional investors held Legend Biotech (LEGN) as of Q2 2024, down from 192 in Q1 2024.
- Funds reported $4.06B of Legend Biotech stock for Q2 2024, down 16% quarter-over-quarter.
- 31 funds opened new Legend Biotech positions in Q2 2024 and 37 closed out, a net change of -6 holders.
- The largest Legend Biotech buyer in Q2 2024 was Westfield Capital Management, an estimated $117M added.
- The largest Legend Biotech seller in Q2 2024 was Capital World Investors, an estimated $134M sold.
Based on aggregated 13F filings for Q2 2024.